Department of Regenerative and Cancer Cell Biology, Albany Medical College, Albany, New York, USA.
The Urological Institute of Northeastern New York, Albany, New York, USA.
FASEB J. 2019 Oct;33(10):10596-10606. doi: 10.1096/fj.201900943R. Epub 2019 Jul 6.
Chronic kidney disease affects >15% of the U.S. population and >850 million individuals worldwide. Fibrosis is the common outcome of many chronic renal disorders and, although the etiology varies (, diabetes, hypertension, ischemia, acute injury, and urologic obstructive disorders), persistently elevated renal TGF-β1 levels result in the relentless progression of fibrotic disease. TGF-β1 orchestrates the multifaceted program of renal fibrogenesis involving proximal tubular dysfunction, failed epithelial recovery and redifferentiation, and subsequent tubulointerstitial fibrosis, eventually leading to chronic renal disease. Recent findings implicate p53 as a cofactor in the TGF-β1-induced signaling pathway and a transcriptional coregulator of several TGF-β1 profibrotic response genes by complexing with receptor-activated SMADs, which are homologous to the small worms (SMA) and mothers against decapentaplegic (MAD) gene families. The cooperative p53-TGF-β1 genomic cluster includes genes involved in cell growth control and extracellular matrix remodeling [, plasminogen activator inhibitor-1 (PAI-1; serine protease inhibitor, clade E, member 1), connective tissue growth factor, and collagen I]. Although the molecular basis for this codependency is unclear, many TGF-β1-responsive genes possess p53 binding motifs. p53 up-regulation and increased p53 phosphorylation; moreover, they are evident in nephrotoxin- and ischemia/reperfusion-induced injury, diabetic nephropathy, ureteral obstructive disease, and kidney allograft rejection. Pharmacologic and genetic approaches that target p53 attenuate expression of the involved genes and mitigate the fibrotic response, confirming a key role for p53 in renal disorders. This review focuses on mechanisms whereby p53 functions as a transcriptional regulator within the TGF-β1 cluster with an emphasis on the potent fibrosis-promoting PAI-1 gene.-Higgins, C. E., Tang, J., Mian, B. M., Higgins, S. P., Gifford, C. C., Conti, D. J., Meldrum, K. K., Samarakoon, R., Higgins, P. J. TGF-β1-p53 cooperativity regulates a profibrotic genomic program in the kidney: molecular mechanisms and clinical implications.
慢性肾脏病影响美国超过 15%的人口和全球超过 8.5 亿人。纤维化是许多慢性肾脏疾病的共同结局,尽管病因不同(如糖尿病、高血压、缺血、急性损伤和泌尿系统梗阻性疾病),但持续升高的肾脏 TGF-β1 水平导致纤维性病无休止地进展。TGF-β1 协调涉及近端肾小管功能障碍、上皮恢复和再分化失败以及随后的肾小管间质纤维化的肾脏纤维化形成的多方面程序,最终导致慢性肾脏病。最近的研究结果表明,p53 是 TGF-β1 诱导的信号通路的辅助因子,也是几个 TGF-β1 促纤维化反应基因的转录核心调节剂,通过与受体激活的 SMAD 形成复合物,SMAD 与小线虫(SMA)和抑制胚胎发育的母基因(MAD)家族同源。协同的 p53-TGF-β1 基因组簇包括参与细胞生长控制和细胞外基质重塑的基因[如纤溶酶原激活物抑制剂-1(PAI-1;丝氨酸蛋白酶抑制剂,E 族,成员 1)、结缔组织生长因子和胶原 I]。虽然这种协同依赖的分子基础尚不清楚,但许多 TGF-β1 反应基因都具有 p53 结合基序。p53 的上调和磷酸化增加;此外,它们在肾毒物和缺血/再灌注损伤、糖尿病肾病、输尿管梗阻性疾病和肾移植排斥中都很明显。针对 p53 的药理学和遗传学方法可降低相关基因的表达并减轻纤维化反应,这证实了 p53 在肾脏疾病中的关键作用。本综述重点介绍了 p53 在 TGF-β1 簇中作为转录调节剂的作用机制,重点介绍了强效促纤维化的 PAI-1 基因。-Higgins, C. E., Tang, J., Mian, B. M., Higgins, S. P., Gifford, C. C., Conti, D. J., Meldrum, K. K., Samarakoon, R., Higgins, P. J. TGF-β1-p53 协同调节肾脏中的促纤维化基因组程序:分子机制和临床意义。